Do Conflicts of Interest Undermine FDA Approval Decisions?
This article was originally published in SRA
Diana Zuckerman says that the latest attempt by the US Food and Drug Administration to prevent conflicts of interest among its advisory committee members is still inadequate.
You may also be interested in...
Licensing agreements and bolt-on acquisitions to strengthen its R&D pipeline are still in Bayer’s sights as the COVID-19 pandemic and currency devaluations have led to the need for job cuts and substantial cost savings at the big pharma company.
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Twenty-seven guidance documents have been posted on the tracker since its last update.
Despite a recent disappointment in a similar partnership with BioNTech, Genentech is pushing ahead with its neoantigen-targeting strategy.